Graphic of pelvic bone and spine with spots highlighted in purple

Xofigo® is the only FDA-approved targeted alpha therapy that treats bone metastases in metastatic castration-resistant prostate cancer1

When prostate cancer goes to the bone, so does Xofigo.1

Xofigo can be absorbed by other organs, primarily the bone marrow and digestive system, which may result in side effects in those healthy tissues.

Learn How Xofigo Can Help Your Patients
Targeted Alpha Therapy uses alpha particles to cause cell death via double-strand DNA breaks

How does Xofigo work?

View Xofigo Mechanism of Action
A man exercising on a treadmill in a gym

Who is the ideal patient for Xofigo therapy?

Who May Benefit From Xofigo
Sample being collected in tubes

See Xofigo efficacy and safety outcomes

Clinical Data

Ordering Xofigo is a simple 3-step process

Order Xofigo Today

Find Xofigo near your practice

Find a Treatment Site
Reference
  • Xofigo® (radium Ra 223 dichloride) injection [prescribing information]. Whippany, NJ: Bayer HealthCare Pharmaceuticals Inc.; December 2019. Return to content